| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Hubei 430071, PRC; AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, PRC
* To whom correspondence should be addressed. Email:
zchen{at}adarc.org.
The severe acute respiratory syndrome (SARS) outbreak in 2002-2003 occurred as a result of zoonotic transmission. Coronavirus (CoV) found in naturally infected palm civet represents the closest genetic relative to SARS-CoV, but the degree and the determinants of cross-neutralization among these viruses remain to be investigated. Studies indicate that the receptor binding domain (RBD) of SARS-CoV spike (S) glycoprotein contains major determinants for viral entry and neutralization. We aim to characterize the impact of natural mutations within the RBDs of civet-CoVs on viral entry and cross-neutralization. In this study, the S-glycoprotein genes were recovered from naturally infected civets in Central China (Hubei province). This extends the geographic distribution of civet-CoV beyond the Southeastern province of Guangdong. Moreover, pseudoviruses generated in our laboratory with four civet S-genes, each with a distinct RBD, infected cells expressing human receptor angiotensin-converting enzyme-2 but with 90-95% less efficiency compared to SARS-CoV. These four civet S-genes were also constructed as DNA vaccines to immunize mice. Immunized sera elicited against most civet S-glycoproteins displayed potent neutralizing activities against autologous viruses but were much less efficient (IC50, 20
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
Natural Mutations in the Receptor Binding Domain of Spike Glycoprotein Determine the Reactivity of Cross-Neutralization between Palm Civet Coronavirus and Severe Acute Respiratory Syndrome Coronavirus
![]()
Abstract
40-fold) at neutralizing SARS-CoV, and vice versa. Convalescent sera from humans were similarly ineffective against the dominant civet-pseudovirus. Our findings suggest that the design of SARS vaccine should not only consider the prevention of re-emergence of SARS-CoV, but also provide cross-protection, thus interrupting zoonotic transmission of a group of genetically divergent civet-CoVs of broad geographic origin.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|